CSMO, Radiochemistry, Clinical & Commercial Manufacturing

Evergreen Theragnostics focuses on developing theragnostic radiopharmaceuticals aimed at improving treatment options for cancer patients. Their innovative pipeline includes several investigational products designed to target specific malignancies, such as neuroendocrine tumors, small cell lung cancer, glioblastoma, pancreatic cancer, and lobular breast cancer. Each product is tailored to bind to unique tumor markers, utilizing isotopes like Gallium-68 and Lutetium-177 for both diagnostic and therapeutic applications. For instance, EVG-001 is a kit for preparing Gallium-68 DOTATOC, which is currently under FDA review for use in PET-CT scans to localize neuroendocrine tumors.

The company employs a fully integrated approach to drug development, collaborating with academic and clinical partners to identify new therapeutic targets. Their products, such as EVG321 and EVG311, are designed to address significant unmet clinical needs, particularly in aggressive cancers like glioblastoma, which has a notably low survival rate. By focusing on molecularly targeted tracers, Evergreen Theragnostics aims to enhance the precision of cancer treatment, potentially offering new hope to patients facing challenging diagnoses.

United States

Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). Our team’s expertise and track record in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management, make us your ideal partner for all of your radiopharmaceutical development, manufacturing, and commercialization needs.

Evergreen Theragnostics

Company Details